Will the Phase 2 trial "SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors" reach primary completion on or before Jun 19, 2028?

Resolves Yes if ClinicalTrials.gov record NCT06936748 (Second Affiliated Hospital of Nanchang University) shows an actual primary completion date on or before Jun 19, 2028. Registered date at generation: Jun 19, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Jun 19, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.